Natasha B. Leighl - Concepedia

Author

Natasha B. Leighl

Also Known As

A Visbal, Geeta Krishna, H Lara-Guerra, Jeffery Hoch, Leighl, Natasha, M. C. Cheung, Michael Ko, N B Leighl, N Leighl, N. B. Leighl

963

Publications

43.4K

Citations

H-Index

164

Concepts

All Affiliations

Princess Margaret Cancer Centre University Health Network University of Toronto Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute

About

Natasha B. Leighl is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	55	161	16K
2	Health Sciences	33	53	6.8K
3	Public Health	11	11	758
4	Nursing	6	6	379
5	Engineering	4	4	97

Natasha B. Leighl

315

Publications

36.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Journal of Clinical Oncology ImmunohematologyCancer ImmunosurveillanceAutoimmune DiseaseMedicineImmunology	2018	3.6K
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial Camilla Zimmermann, Nadia Swami, Monika K. Krzyzanowska, The Lancet Palliative CareFamily MedicineAdvanced CancerCluster-randomised Controlled TrialEnd-of-life Care	2014	1.7K
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Martin Reck, Joachim von Pawel, Petr Zatloukal, Journal of Clinical Oncology	2009	1.5K
Sensitive tumour detection and classification using plasma cell-free DNA methylomes Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Nature Cancer ResearchChromatinSensitive Tumour DetectionCancer DetectionMedicine	2018	974
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Journal of Clinical Oncology	2018	763
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Nasser H. Hanna, David H. Johnson, Sarah Temin, Journal of Clinical Oncology	2017	643
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Keunchil Park, Eric B. Haura, Natasha B. Leighl, Journal of Clinical Oncology	2021	597
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Clinical Cancer Research	2019	584
Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis Rebecca Hagerty, Phyllis Butow, Peter Ellis, Journal of Clinical Oncology	2005	577

Page 1